Element Biosciences launched Vitari, a high‑throughput sequencing platform the company says can deliver 3 terabases per paired‑end 150 bp run in 36 hours and sequence a 30X human genome for roughly $100 in consumables. Element positioned Vitari as a cost and throughput disruptor for large‑scale genomics, clinical sequencing labs, and population studies. The platform’s throughput and per‑sample economics could reshape sequencing procurement and study design, but adoption will hinge on ecosystem support — library prep, informatics and validation for clinical use. Element emphasized throughput consistency and operational scalability as critical selling points for core labs and research consortia.